CSF1R and early-onset autosomal dominant Alzheimer disease: The ability to deplete microglia via CSF1R inhibition, based on mouse model studies, was recently recognized as a possible therapeutic strategy for the treatment of several brain diseases associated with inflammation, including Alzheimer's disease (Spangenberg and Green, 2017; Spangenberg et al., 2019; Casali et al., 2020; Hansen et al., 2018) and glioma (Akkari et al., 2020).